[6-甲基氨基-2-(2-甲基丙酰氧基)-5,6,7,8-四氢萘-1-基]2-甲基丙酸酯 | 90060-42-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: [6-甲基氨基-2-(2-甲基丙酰氧基)-5,6,7,8-四氢萘-1-基]2-甲基丙酸酯
• 英文名称: Nolomirole
• 英文别名: [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate
• CAS: 90060-42-7
• 化学式: C₁₉H₂₇NO₄
• 分子量: 333.4
• InChiKey: OMMYLOLVPCCZQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
  申请人：——

  公开号：US20040102652A1

  公开（公告）日：2004-05-27

  The use of the optically active forms of 5,6-dihydroxy-2-methylaminotetralin and acyl esters thereof as medicaments for cardiovascular diseases a process for the preparation thereof and their use in pharmaceutical compositions.

  将5,6-二羟基-2-甲基氨基四氢萘及其酰基酯的光学活性形式用作心血管疾病药物的使用，以及制备这些药物的过程和它们在药物组合物中的使用。
• Process for the manufacture of form I of nolomirole hydrochloride
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：EP1384708A1

  公开（公告）日：2004-01-28

  A process for the preparation and isolation of the pharmaceutical chemical compound nolomirole hydrochloride in a highly purified crystalline Form I, as well as pharmaceutical preparations thereof for the treatment of patients suffering of cardiovascular diseases such as congestive heart failure and hypertension are described.

  本文描述了一种制备和分离药用化学物质nolomirole hydrochloride的过程，以高度纯化的结晶形式I，以及用于治疗心血管疾病（如充血性心力衰竭和高血压）患者的药物制剂。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Aminotetralin derivative for the therapy of cardiovascular diseases
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：EP1216702A2

  公开（公告）日：2002-06-26

  The use of 5,6-diisobutyroyloxy-2-methylaminotetralin in the preparation of pharmaceutical compositions for the therapy of cardiac disorders, particularly of congestive heart failure.

  5,6-二异丁酰氧基-2-甲氨基四氢萘在制备治疗心脏疾病，尤其是充血性心力衰竭的药物组合物中的应用。
• Aminotetralin Derivative for the Therapy of Cardiovascular Diseases
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：EP1331004A3

  公开（公告）日：2003-08-06

  Left ventricular dysfunctions is treated by a process, comprising: administering to a subject suffering from left ventricular remodeling a therapeutically effective amount of 5,6-dihydroxy-2-methylaminotetralin, or 5,6-diisobutyroyloxy-2-methylaminotetralin, or a pharmaceutically acceptable salt thereof.

  左心室功能障碍的治疗方法包括：向患有左心室重塑的受试者施用治疗有效量的 5,6-二羟基-2-甲氨基四氢萘，或 5,6-二异丁酰氧基-2-甲氨基四氢萘，或其药学上可接受的盐。